Guidelines : Additional lines of treatment (high cost drugs)
Detail
Condition :
Additional lines of treatment (high cost drugs)
Keywords :
sequential, RMOC, additional, Biologic, NICE, JAK, Cytokine modulator, immunosuppressant, monoclonal antibody, biosimilar, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, csDMARD, conventional synthetic, targeted synthetic, tsDMARD, 4th line
RA (severe), RA (moderate), AS, NrSpA, PsA, Crohn's, UC, IBD, Psoriasis, Rheumatology, Dermatology, ankylosing spondylitis, non-radiographic spondyloarthritis, rheumatoid arthritis, ulcerative colitis, interleukin, IL-6, janus kinase inhibitor, sequential, additional, vedolizumab, adalimumab, infliximab, ustekinumab, etanercept, golimumab, guselkumab, tocolizumab, rituximab, ixekizumab, secukinumab, baracitinib, upadacitinib, certolizumab, filgotinib, sarilumab, apremilast, bimekizumab, brodalumab, dimethyl fumarate, risankizumab, tildrakizumab
Committee Recommendations
Date
Committee Name
Narrative
Traffic Light Status
05 July 2023
The Surrey Heartlands ICS Area Prescribing Committee (APC) has agreed an additional lines of treatment process and principles in conjunction with the local Rheumatology, Gastroenterology and Dermatology Clinical Networks.
Currently, this process including MDT discussions is required at the following points in the treatment pathway:
- 4th line or subsequent-line treatment choice in severe rheumatoid arthritis, psoriatic arthritis, IBD, and psoriasis pathways
- 3rd line treatment choice in moderate rheumatoid arthritis
Please send the completed request form entitled ‘Additional lines of treatment – Request form – April 2023’ (in the ‘Documents’ section below) to highcost.drugs@nhs.net using NHSmail.
N/A
Documents
Type
Document
Review Date
Supplementary documents (CCG specific documents)
No records returned.
Drugs
Below are listed drugs that are used to treat Additional lines of treatment (high cost drugs) .
- No records returned.